Accelerate your CDMO or DTC pipeline. Map the exact physiochemical constraints, bioavailability synergies, and optimal delivery mechanisms for Cetyl Myristoleate.
Cetyl myristoleate acts as a unique fatty acid ester that modulates the inflammatory response by inhibiting 5-lipoxygenase and stabilizing lysosomal membranes, primarily utilized for improving joint mobility and mitigating symptoms of osteoarthritis.
5364509
296.5 g/mol
7.6
methyl (Z)-octadec-9-enoate
Every active compound behaves uniquely based on the physical matrix it is suspended in. Below are the known physical chemistry challenges for Cetyl Myristoleate across standard consumer modalities.
The waxy, low-melting-point nature of cetyl myristoleate requires specialized excipients or liquid-fill technology to prevent leakage and ensure stability in dry powder blends.
High lipid content can interfere with pectin or gelatin cross-linking, potentially leading to oil leaching and compromised structural integrity of the gummy matrix.
The high therapeutic dose required and the hydrophobic nature of the molecule significantly exceed the payload capacity and film-forming capabilities of standard pullulan or HPMC oral thin films.
Ready to launch a product featuring Cetyl Myristoleate? Skip months of expensive wet-lab iterations. Generate a manufacturer-ready formulation in hours, instantly screened for physical incompatibilities and global regulatory compliance.
Build Science-Backed FormulationNeed absolute proof that your Cetyl Myristoleate extract actually absorbs? Stop blindly combining generic powders. Run a physics-based PBPK simulation to mathematically engineer peak clinical efficacy and targeted plasma concentrations.
Simulate BioavailabilityIs your Cetyl Myristoleate payload degrading in the capsule before the expiration date? Stop waiting for costly bench testing. Run an accelerated digital twin to precisely model oxidation pathways and pH shifts before finalizing a manufacturing run.
Model Active Degradation